Opus Genetics, Inc.
IRDHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeOpus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of. The $288.7M market capitalization puts IRD squarely in micro-cap range for its industry. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Market Cap
$288.7M
Beta
0.62
P/E (TTM)
—
P/E (Fwd)
-4.85
EPS (TTM)
$-1.15
EPS (Fwd)
$-0.71
ROE
-4796.5%
ROA
-48.1%
Cash
$88.8M
Total Debt
$36.2M
Free CF
-$38.6M
52W Change
74.4%
Annual Financials
Cash vs Debt
Where IRD stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, IRD finished 13.38% below its 150-day moving average ($4.41) and 7.06% below its 200-day moving average ($4.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IRD overbought or oversold?
At the October 20, 2026 close, IRD's RSI(14) was 18.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $88.8M in cash and $36.2M in debt, IRD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$38.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -4796.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $39.9M (2022) to $14.2M (2025), a 64% decline worth watching.
IRD's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, IRD has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Opus Genetics, Inc.'s trajectory.